The Incidence of Familial Nonmedullary Thyroid Cancer in a Large Case Series

Abstract

Familial nonmedullary carcinoma of the thyroid gland occurs very rarely.

Familial nonmedullary thyroid carcinoma—clinical relevance and prognosis. A European multicenter study

“…FNMTC patients with tumor recurrence-as far as stated in literature-were predominantly younger than 45 years [9,17,18]. Lupoli et al presented three of seven patients (age 22, 26, and 46 years) with vascular invasive, multifocal, and bilateral FNMTC with a tumor relapse, 3 to 6 years after surgery with one patient dying of lung metastases [18].…”

“…Lupoli et al presented three of seven patients (age 22, 26, and 46 years) with vascular invasive, multifocal, and bilateral FNMTC with a tumor relapse, 3 to 6 years after surgery with one patient dying of lung metastases [18]. Zivalijevic et al reported in a series of 13 FNMTC (I:II-IV staging ratio10:3) two patients with relapse after 11 and 12 years after thyroidectomy with age at diagnosis of 33 and 42 years [9]. Grossman reported recurrence in eight of 14 patients.…”

“…Since the first description of familial nonmedullary thyroid cancer by Robinson and Or in 1955 [5], several smaller and some larger FNMTC series were reported [3,4,6,8,9,11]. We analyzed 41 patients with FNMTC and found slightly younger patients (median 42 years) compared with the mean age of patients diagnosed with differentiated thyroid carcinomas (49 years) [13].…”

“…If the diagnosis of FNMTC is based on affection of at least two first-degree relatives, familial forms are found in about 2% to 6% of patients with differentiated thyroid carcinomas [6][7][8][9]. Reviews of the different family trees and several genetic studies indicate that FNMTC is genetically heterogeneous.…”

Savremeno hirursko lecenje diferentovanih malignih tumora stitaste zlezde - sta smo postigli u toku poslednje dve decenije

“…Uglavnom se radi o naknadno utvrđenoj rodbinskoj vezi posle operativnog lečenja papilarnih tumora dijagnostikovanih citološkom analizom ili histopatološkim nalazima. U svakom slučaju, nodoznim promenama bliskih srodnika bolesnika sa malignim tumorima štitaste žlezde posvećuje se posebna pažnja (17).…”